Chromene Modulators Targeting CCR-2 Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases, autoimmune disorders, and transplant rejection often rely on incomplete or ineffective methods, as existing therapies fail to adequately address the underlying chemokine-mediated inflammation and immune responses.
Innovation Solution
Development of novel chromene derivatives that act as antagonists or partial agonists/antagonists of MCP-1 or CCR-2 receptor activity, administered as pharmaceutical compositions to modulate chemokine and chemokine receptor activity, thereby reducing inflammatory responses and immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for inflammatory diseases and autoimmune disorders, then treatment is provided, but the therapies are incomplete or ineffective in addressing chemokine-mediated inflammation
Solution Approach 1:
The patent employs parameter changes by developing novel chromene derivative compounds with specific molecular structures (Formula I) that have optimized binding affinity and selectivity for CCR-2 and CCR-5 receptors. By modifying chemical parameters such as substituent groups (R1-R6, W1-W3, Y, Z) and molecular properties, the invention achieves enhanced therapeutic effectiveness and specificity for chemokine-mediated inflammatory pathways compared to existing therapies.
2Adaptability or versatility
If current treatment methods are applied, then general inflammatory responses are addressed, but specific chemokine receptor pathways (MCP-1/CCR-2) are not adequately targeted
Solution Approach 1:
The patent applies local quality by designing chromene derivatives with specific molecular characteristics that enable selective interaction with particular chemokine receptors (CCR-2 and CCR-5) rather than broad-spectrum inhibition. The compounds exhibit localized specificity through their chemical structure, targeting specific pathways (MCP-1/CCR-2, RANTES/CCR-5) involved in inflammatory diseases, thereby providing precise therapeutic action on chemokine-mediated inflammation while sparing other physiological processes.
3Reliability
If broad-spectrum anti-inflammatory therapies are used, then general inflammation is reduced, but selective modulation of chemokine receptors is achieved
Solution Approach 1:
The patent utilizes composite materials by creating chromene derivative compounds that integrate multiple functional groups and structural elements into a single molecular entity. The compounds combine the chromene core structure with various substituent groups (alkyl, alkoxy, halo, amino groups) and heterocyclic moieties (W1-W3 containing N, O, or S atoms), forming composite molecular structures that achieve both effective inflammation reduction through CCR-2/CCR-5 antagonism and optimized pharmacological properties.
Data Source
AI summary
The present application describes modulators of MCP-1 or CCR-2 of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W1, W2, W3, Y, Z, R2, R3, R3′ and R4, are defined in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.